Prophylactic use of fluconazole in neutropnic cancer patients精选.pdfVIP

Downloaded from on October 24, 2012 - Published by Postgrad MedJ7 1995; 71: 284-286 C) The Fellowship of Postgraduate Medicine, 1995 Original articles Prophylactic use of fluconazole in neutropenic cancer patients Kadri Yamaq, Esin $enol, Rauf Haznedar Summary below 2000/41. The mean neutrophil counts This study was carried out on 70 patients were 822 ± 645/il (range 0- 1908/tl). with haematological or solid malignan- Patients were randomly assigned to receive cies who were receiving chemotherapy or not to receive prophylaxis with fluconazole. and/or radiotherapy. Forty-one patients Prophylaxis was given to 41 patients; 29 were randomly assigned to receive fluc- patients did not receive any prophylaxis. onazole, 400 mg/day, while they were Fluconazole was given orally in a dose of neutropenic. Systemic fungal infection 400 mg daily in two divided doses. Treatment developed in four of the 41 patients (9%) was continued until the neutrophil count had receiving prophylaxis in comparison to increased to 2000/41 or until systemic fungal nine of 29 patients (31%) not receiving infection was suspected. During the treatment prophylaxis. The incidence of systemic period cultures ofthroat, feces, urine and blood fungal infection was significantly dif